1. Home
  2. FTAIN vs XGN Comparison

FTAIN vs XGN Comparison

Compare FTAIN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FTAIN

FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares

HOLD

Current Price

$25.33

Market Cap

0.0

Sector

Industrials

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$6.08

Market Cap

138.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTAIN
XGN
Founded
N/A
2002
Country
United States
United States
Employees
580
N/A
Industry
Misc Corporate Leasing Services
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
138.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FTAIN
XGN
Price
$25.33
$6.08
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$13.67
AVG Volume (30 Days)
N/A
295.4K
Earning Date
N/A
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$63,599,000.00
Revenue This Year
N/A
$21.76
Revenue Next Year
N/A
$15.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.08
52 Week Low
N/A
$2.67
52 Week High
N/A
$12.23

Technical Indicators

Market Signals
Indicator
FTAIN
XGN
Relative Strength Index (RSI) 47.75 28.31
Support Level $25.33 $5.84
Resistance Level $25.53 $6.34
Average True Range (ATR) 0.10 0.33
MACD 0.01 0.04
Stochastic Oscillator 53.32 18.97

Price Performance

Historical Comparison
FTAIN
XGN

About FTAIN FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares

FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: